Bio-Path receives noncompliance letter from Nasdaq

In a regulatory filing, Bio-Path Holdings announced that it received a deficiency letter from the Listing Qualifications Department of Nasdaq notifying the company that it is not in compliance with the minimum stockholders’ equity requirement of at least $2.5M for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550. The letter has no effect on the listing of the company’s common stock at this time, and the company’s common stock will continue to trade on Nasdaq.